2018 Pipeline Review for Anaplastic Oligoastrocytoma: H1 Analysis by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type - ResearchAndMarkets.com
Jun. 11, 2018
DUBLIN--(BUSINESS WIRE)--Jun 11, 2018--The "Anaplastic Oligoastrocytoma - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.
This latest pipeline guide provides comprehensive information on the therapeutics under development for Anaplastic Oligoastrocytoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The pipeline guide also reviews of key players involved in therapeutic development for Anaplastic Oligoastrocytoma and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II and Phase I stages are 4 and 3 respectively.
Companies MentionedAbbVie Inc Astellas Pharma Inc Boehringer Ingelheim GmbH Novartis AG Pfizer Inc
Key Topics CoveredIntroduction Report Coverage Anaplastic Oligoastrocytoma - Overview Anaplastic Oligoastrocytoma - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Anaplastic Oligoastrocytoma - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Anaplastic Oligoastrocytoma - Companies Involved in Therapeutics Development Anaplastic Oligoastrocytoma - Drug Profiles
For more information about this report visit https://www.researchandmarkets.com/research/8q8w8c/2018_pipeline?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180611005941/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Brain Cancer Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 06/11/2018 01:23 PM/DISC: 06/11/2018 01:23 PM